Globus Medical (GMED) EVP executes options, sells 20,000 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Globus Medical EVP and General Counsel Kelly Huller reported option exercises and a share sale involving Class A common stock. On February 25, 2026, Huller exercised stock options for 20,000 shares granted on January 22, 2019, which are described as fully vested.

The option exercise was reported at a price of $43.58 per share, resulting in direct ownership of 20,000 shares of Class A common stock. That same day, Huller sold 20,000 shares of Class A common stock at $94.50 per share, leaving no shares reported as directly owned after the sale.

The filing notes that the sale was carried out under a Rule 10b5-1 trading plan dated November 12, 2025, indicating the sale was pre‑scheduled rather than newly decided at the time of the transaction.

Insider Trade Summary

Net Seller: 20,000 shares ($1,890,000)

Net Sell 3 txns

Insider Huller Kelly

Role EVP, GC, Corporate Secretary

Sold 20,000 shs ($1.89M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy Class A Common Stock)	20,000	$0.00	--
Exercise	Class A Common Stock	20,000	$43.58	$872K
Sale	Class A Common Stock	20,000	$94.50	$1.89M

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 20,000 shares (Direct); Class A Common Stock — 20,000 shares (Direct)

Footnotes (1)

This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated November 12, 2025 executed by the reporting person. These options were granted on January 22, 2019 and are fully vested.

Form 4 Insider Transactions: What Each Field Means →

02/27/2026 - 05:53 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huller Kelly

(Last)

(First)

(Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON

19403

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, GC, Corporate Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/25/2026		M		20,000	A	$43.58	20,000	D
Class A Common Stock	02/25/2026		S⁽¹⁾		20,000	D	$94.5	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy Class A Common Stock)	$43.58	02/25/2026		M			20,000	⁽²⁾	01/22/2029	Class A Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated November 12, 2025 executed by the reporting person.

2. These options were granted on January 22, 2019 and are fully vested.

	/s/ Kelly G. Huller	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Globus Medical (GMED) insider Kelly Huller report on this Form 4?

Kelly Huller reported exercising stock options for 20,000 shares and selling 20,000 shares of Globus Medical Class A common stock. The transactions occurred on February 25, 2026 and changed reported direct ownership from 20,000 shares to zero.

How many Globus Medical (GMED) shares did Kelly Huller sell and at what price?

Kelly Huller sold 20,000 shares of Globus Medical Class A common stock at $94.50 per share. The sale took place on February 25, 2026 and was reported as an open‑market or private transaction on Form 4.

Were Kelly Huller’s Globus Medical (GMED) stock sales under a 10b5-1 plan?

Yes. The filing states the 20,000‑share sale was effectuated under a Rule 10b5‑1 trading plan dated November 12, 2025. Such plans pre‑schedule trades to help insiders systematically sell shares over time.

What stock options did Kelly Huller exercise in this Globus Medical (GMED) Form 4?

Huller exercised stock options covering 20,000 shares of Globus Medical Class A common stock. The options were originally granted on January 22, 2019 and are described in the filing as fully vested at the time of exercise.

What is Kelly Huller’s role at Globus Medical (GMED) according to the Form 4?

Kelly Huller is identified as an officer of Globus Medical with the title EVP, General Counsel, and Corporate Secretary. The reported transactions therefore reflect trading activity by a senior executive of the company’s leadership team.